Medicenna Therapeutics Corp.

OTCPK:MDNA.F Stock Report

Market Cap: US$26.3m

Medicenna Therapeutics Management

Management criteria checks 2/4

Medicenna Therapeutics' CEO is Fahar Merchant, appointed in Oct 2011, has a tenure of 14.67 years. total yearly compensation is CA$1.33M, comprised of 34.9% salary and 65.1% bonuses, including company stock and options. directly owns 6.08% of the company’s shares, worth $1.60M. The average tenure of the management team and the board of directors is 8.9 years and 4.4 years respectively.

Key information

Fahar Merchant

Chief executive officer

CA$1.3m

Total compensation

CEO salary percentage34.86%
CEO tenure14.7yrs
CEO ownership6.1%
Management average tenure8.9yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 30

Medicenna extends period to exercise certain warrants

Medicenna Therapeutics (NASDAQ:MDNA) received conditional approval from the TSX to extend the expiry date of the common share purchase warrants of the company originally issued on October 17, 2019. The warrants, of which 1,549,052 are available to be extended, are exercisable for common shares of the company at a price of $1.75/common share and are set to expire on October 17, 2022,  will now expire on July 17, 2023, an extension of 9 months. All other terms of the warrants, including the exercise price, remain unchanged. There are 1,661,552 warrants remaining available for exercise including 112,500 warrants held directly or indirectly by insiders of the company which will not be extended.
Seeking Alpha • Sep 13

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Medicenna Therapeutics (NASDAQ:MDNA) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate its agonist in combination with cancer drug Keytruda in its ongoing phase 1/2 study named ABILITY. Medicenna's (MDNA) agonist, MDNA11, is being assessed in the early- to mid-stage trial as a monotherapy and in combination with MRK's Keytruda to treat patients with cancerous tumors. As per the clinical trial collaboration deal, MDNA will sponsor the study and MRK will supply Keytruda. "Although we believe that MDNA11 has great potential as a single agent, combining it with Keytruda may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11," MDNA CEO Fahar Merchant said in a statement. MDNA stock +1.5% to $1.03 in afternoon trading.
Seeking Alpha • Aug 15

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics press release (NASDAQ:MDNA): Q1 GAAP EPS of -$0.07 in-line. Medicenna had cash, cash equivalents, and marketable securities of $19.3 million at June 30, 2022, compared to $20.5 million at March 31, 2022.
Seeking Alpha • Aug 08

Medicenna Therapeutics stock slides on launch of units offering

Medicenna Therapeutics (NASDAQ:MDNA) shares fell 6% in Monday's extended session after the immunotherapy company announced the launch of an underwritten public offering of units in the U.S. Each unit will be comprised of one common share and one warrant to purchase common shares. The offering is expected to be priced in the context of the market, with the final terms to be determined at the time of pricing. The company plans to use the net proceeds primarily to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, working capital and for general corporate purposes.

CEO Compensation Analysis

How has Fahar Merchant's remuneration changed compared to Medicenna Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-CA$18m

Dec 31 2025n/an/a

-CA$13m

Sep 30 2025n/an/a

-CA$14m

Jun 30 2025n/an/a

-CA$13m

Mar 31 2025CA$1mCA$465k

-CA$12m

Dec 31 2024n/an/a

-CA$27m

Sep 30 2024n/an/a

-CA$27m

Jun 30 2024n/an/a

-CA$26m

Mar 31 2024CA$1mCA$519k

-CA$25m

Dec 31 2023n/an/a

-CA$15m

Sep 30 2023n/an/a

-CA$12m

Jun 30 2023n/an/a

-CA$9m

Mar 31 2023CA$877kCA$428k

-CA$10m

Dec 31 2022n/an/a

-CA$9m

Sep 30 2022n/an/a

-CA$13m

Jun 30 2022n/an/a

-CA$20m

Mar 31 2022CA$894kCA$436k

-CA$23m

Dec 31 2021n/an/a

-CA$25m

Sep 30 2021n/an/a

-CA$26m

Jun 30 2021n/an/a

-CA$21m

Mar 31 2021CA$868kCA$543k

-CA$17m

Dec 31 2020n/an/a

-CA$14m

Sep 30 2020n/an/a

-CA$11m

Jun 30 2020n/an/a

-CA$9m

Mar 31 2020CA$852kCA$411k

-CA$8m

Compensation vs Market: Fahar's total compensation ($USD939.15K) is above average for companies of similar size in the US market ($USD647.34K).

Compensation vs Earnings: Fahar's compensation has increased whilst the company is unprofitable.

CEO

Fahar Merchant (69 yo)

14.7yrs
Tenure
CA$1,333,900
Compensation

Dr. Fahar Merchant, Ph.D. serves as the Chairman, Chief Executive Officer and President at A2 Acquisition Corp. Dr. Merchant has been President and Chief Executive Officer and Director of Medicenna Therape...

Leadership Team

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder14.7yrsCA$1.33m6.08%
$ 1.6m
Rosemina Merchant
Founder & Chief Development Officer15.2yrsCA$982.80k6.06%
$ 1.6m
David Hyman
Chief Financial Officer2.4yrsCA$446.00k0.11%
$ 28.5k
Nageatte Ibrahim
Chief Medical Officerless than a yearno datano data
Samuel Denmeade
Scientific Advisorno datano datano data
8.9yrs
Average Tenure
69yo
Average Age

Experienced Management: MDNA.F's management team is seasoned and experienced (8.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder14.7yrsCA$1.33m6.08%
$ 1.6m
John Geltosky
Independent Director5.8yrsCA$202.00kno data
Albert Beraldo
Lead Independent Director9.6yrsCA$234.50k0.95%
$ 251.0k
Karim Lalji
Independent Director1.8yrsCA$167.00kno data
Lillian Siu
Member of Clinical Advisory Board4.3yrsno datano data
David Mooney
Member of Scientific Advisory Board4.4yrsno datano data
Sergio Quezada
Chairman of Scientific Advisory Board4.4yrsno datano data
Paolo Ascierto
Member of Clinical Advisory Board4.3yrsno datano data
Burkhard Becher
Member of Scientific Advisory Board4.4yrsno datano data
William Redmond
Member of Scientific Advisory Board4.4yrsno datano data
Hussein Tawbi
Member of Clinical Advisory Board4.3yrsno datano data
Richard Sutin
Directorless than a yearno data0.025%
$ 6.6k
4.4yrs
Average Tenure
71yo
Average Age

Experienced Board: MDNA.F's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 07:21
End of Day Share Price 2026/06/29 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicenna Therapeutics Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles ZhuGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.
Dev PrasadLucid Capital Markets